Upgrade to SI Premium - Free Trial

Form SCHEDULE 13G/A SAB Biotherapeutics, Filed by: Woodline Partners LP

August 14, 2026 11:04 AM





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: Consists of (i) 1,180,355 shares of Common Stock (as defined in Item 2(a)), (ii) 2,850,000 shares of Common Stock issuable upon conversion of 28,500 shares of Series B preferred stock (the "Series B Preferred Stock") underlying 28,500 enrollment warrants (the "Enrollment Warrants") and (iii) 1,425,000 shares of Common Stock issuable upon conversion of 14,250 shares of Series B Preferred Stock underlying 14,250 data release warrants (the "Data Release Warrants").


SCHEDULE 13G



Woodline Partners LP
Signature:/s/ Erin Mullen
Name/Title:By: Erin Mullen, General Counsel & Chief Compliance Officer
Date:08/14/2026

Categories

SEC Filings